COMMUNIQUÉS West-GlobeNewswire

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

16/08/2024 - 12:45

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its primary immunogenicity [...]

Immuron Announces New U.S. Department of Defense Research Award for Naval Medical Research Command and Walter Reed Army Institute of Research to advance Travelan®

16/08/2024 - 12:00

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited ( [...]

Vistin Pharma ASA: Invitation to Q2 2024 conference call

16/08/2024 - 10:00

Oslo, Norway, 16 August 2024 Vistin Pharma ASA will release its second quarter and YTD 2024 results on Friday 23 rd of August 2024. Vistin Pharma will host a conference call for all shareholders and interested parties [...]

Aino Health AB (publ): interim report january-june 2024

16/08/2024 - 08:30

This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. Extending contracts. Improved cash flow. January – June 2024 • Net sales were KSEK 12 [...]

NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED)

16/08/2024 - 08:00

Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 – JUNE 30, 2024 (UNAUDITED) NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST HALF OF THE YEAR [...]

Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

16/08/2024 - 07:30

Interim results from clinical study show non-inferiority of immune responses from mpox/smallpox vaccination in adolescents and similar safety profile compared to adults, supporting the extension of current approval in [...]

Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference

16/08/2024 - 00:14

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive [...]

Precipio Announces Q2-2024 Shareholder Update Call

15/08/2024 - 23:00

Conference Call to be held on August 19, 2024 at 5:00 PM EDT NEW HAVEN, Conn., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2024 corporate [...]

Aptose Announces Adjournment of its Special Meeting of Shareholders

15/08/2024 - 22:30

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

15/08/2024 - 22:15

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190% increase from the same [...]

Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

15/08/2024 - 22:15

Record Total Revenues of $236 million for the first six months of 2024, an over ten-fold increase compared to same period in 2023 Product revenues for the first six months were $66 million, a 190% increase from the same [...]

Certara Launches Phoenix™ Version 8.5 Drug Development Software

15/08/2024 - 22:15

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry [...]

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

15/08/2024 - 22:15

Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader [...]

Codexis Publishes FY2023 Sustainability Disclosures

15/08/2024 - 22:05

Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board REDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today [...]

Vericel Announces FDA Approval of NexoBrid for the Treatment of Pediatric Patients with Severe Thermal Burns

15/08/2024 - 22:05

Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for [...]

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

15/08/2024 - 22:05

The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively on August 16, 2024 MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- [...]

ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board

15/08/2024 - 22:05

DelOrefice is the Chief Financial Officer at BD, one of the largest global MedTech companies in the world Board appointment brings over 30 years of strategic and operational finance expertise SAN DIEGO, Aug. 15, 2024 ( [...]

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

15/08/2024 - 22:03

Company demonstrates reliable production from multiple biological sources These manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring consistency while maintaining [...]

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15/08/2024 - 22:01

BEDFORD, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on August 1, 2024, Anika granted non [...]